Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk

Česká verzia

Authors: J. Widimský jr.
Authors place of work: Centrum pro hypertenzi III. interní kliniky 1. lékařské fakulty UK a VFN v Praze, přednosta prof. MU Dr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2013; 59(6): 501-504
Category: 80th birthday prof. MUDr. Karla Horkého, DrSc., FACP (Hon.)

Summary

Primary hyperaldosteronism (PH) is common cause of secondary hypertension with autonomous aldosterone overproduction by adrenal cortex with high plasma aldosterone, suppressed renin and high blood pressure. Patients with PH have compared to essential hypertension (EH) more frequent sublinical organ damage and higher cardiovascular risk (CV). Higher carotid IMT, arterial stiffness and microalbuminuria was found in PH. Early specific therapy of PH may lead to the regression of target organ damage and decrease of CV risk. Early diagnostic and therapeutic measures are very important due to high prevalence of PH.

Key words:
primary hyperaldosteronism – hypertension – cardiovascular risk

Zdroje

1. Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrom. J Lab Clin Med 1955; 43: 317.

2. Litynski M. Nadcisnienie tetnicze wyvolane guzami korowo‑ nad‑ nerczowymi. Pol Tyg Lek 1953; 8: 204– 208.

3. Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2008; 93: 3266– 3281.

4. Štrauch B, Zelinka T, Widimský J jr. et al. Prevalence of primary hyperaldosteronism in middle Europe region. J Human Hypertens 2003; 17: 349– 352.

5. Widimský J jr. Primární hyperaldosetronismus: epidemie anebo jen častá příčina sekundární hypertenze? Cor Vasa 2008; 50: 366– 367.

6. Rizzoni D, Paiardi S, Rodella L et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638– 2642.

7. Holaj R, Zelinka T, Wichterle D et al. Increased intima‑ media thickness of the common artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451– 1457.

8. Štrauch B, Petrák O, Wichterle D et al. Increased Arterial Wall Stiffness in Primary Aldosteronism in Comparison with Essential Hypertension. Am J Hypertens 2006; 19: 909– 914.

9. Widimsky J jr., Strauch B, Petrák O et al. Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney Blood Pressure Res 2012; 35: 529– 533.

10. Muiesan ML, Salvetti M, Paini A et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529– 534.

11. Milliez P et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Col Cardiol 2005; 45: 1243– 1248.

12. Rossi GP, Bernini G, Caliumi C et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. J Am Col Cardiol 2006; 48: 2293– 2300.

13. Rossi GP, Bernini G, Desideri G et al. PAPY Study Participants Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232– 238.

14. Born‑ Frontsberg E, Reincke M, Rump LC et al. Participants of the German Conn‘s Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn‘s Registry. J Clin Endocrinol Metab 2009; 94: 1125– 1130.

15. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80– 85.

16. Reincke M, Fischer E, Gerum S et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension 2012; 60: 618– 624.

17. Krug AW, Ehrhart‑ Bornstein M. Aldosterone and Metabolic Syndrome: Is Increased Aldosterone in Metabolic Syndrome Patients an Additional Risk Factor? Hypertension 2008; 51: 1252– 1258.

18. Sowers JR, Whaley‑ Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776– 783.

19. Fallo F, Veglio F, Bertello C et al. Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. J Clin Endocrinol Metab 2006; 91: 454– 459.

20. Fallo F, Federspil G, Veglio F et al. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep 2007; 9: 106– 111.

21. Šomlóová Z, Widimský J jr., Rosa J et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens 2010; 24: 625– 630.